Alumis Inc. ALMS
6.62 USD +0.22 (+3.44%)
At closeNov 11, 2026, 4:01 PM EST
6.62 0.00 0.00%
After hours · Nov 11, 4:01 PM ET
6.43 Day range 6.72
4.60 52-week range 31.35
- YTD
- -32.17%
- 1 year
- +24.91%
News
defenseworld.net Alumis Inc. (NASDAQ:ALMS) Stock Has Consensus Target Price of $33.27 According to Brokerages Shares of Alumis Inc. (NASDAQ: ALMS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the fourteen research firms that are covering the stock, Marketbeat.com reports.…
defenseworld.net Alumis Inc. (NASDAQ:ALMS) Stock Has Consensus Target Price of $33.27 Alumis Inc. (NASDAQ: ALMS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fourteen ratings firms that are covering the company, MarketBeat Ratings reports. One…
benzinga.com Alumis New Phase 3 ONWARD Data Show Envudeucitinib Improved Scalp, Itch And Quality Of Life In Psoriasis, Building On 54% PASI 100 At Week 48; NDA On Track For 4Q 2026 – Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis–…
globenewswire.com Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures – Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib's potential to become a leading oral therapy for moderate-to-severe plaque psoriasis –…
defenseworld.net Tango Therapeutics (NASDAQ:TNGX) vs. Alumis (NASDAQ:ALMS) Financial Analysis Tango Therapeutics (NASDAQ: TNGX - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses…
defenseworld.net Alumis (NASDAQ:ALMS) & Pyxis Oncology (NASDAQ:PYXS) Head-To-Head Review Pyxis Oncology (NASDAQ: PYXS - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two…
defenseworld.net Financial Survey: Alvotech (NASDAQ:ALVO) & Alumis (NASDAQ:ALMS) Alumis (NASDAQ: ALMS - Get Free Report) and Alvotech (NASDAQ: ALVO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies…
seekingalpha.com Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
defenseworld.net 226,618 Shares in Alumis Inc. $ALMS Bought by Bank of New York Mellon Corp Bank of New York Mellon Corp acquired a new stake in Alumis Inc. (NASDAQ: ALMS) during the second quarter, according to its most recent filing with the SEC. The firm acquired 226,618 shares of the…
globenewswire.com Alumis to Participate in Upcoming September Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with…
benzinga.com Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $37 Oppenheimer analyst Jeff Jones maintains Alumis (NASDAQ:ALMS) with a Outperform and lowers the price target from $55 to $37.
benzinga.com Wells Fargo Maintains Overweight on Alumis, Lowers Price Target to $25 Wells Fargo analyst Derek Archila maintains Alumis (NASDAQ:ALMS) with a Overweight and lowers the price target from $51 to $25.
benzinga.com Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
benzinga.com This OGE Energy Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday Analysts upgraded Alumis, Sirius XM, OGE Energy, revising their price targets and outlooks.- benzinga.com Morgan Stanley Maintains Overweight on Alumis, Lowers Price Target to $29 Morgan Stanley analyst Terence Flynn maintains Alumis (NASDAQ:ALMS) with a Overweight and lowers the price target from $39 to $29.
benzinga.com HC Wainwright & Co. Upgrades Alumis to Buy, Lowers Price Target to $15 HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Alumis (NASDAQ:ALMS) from Neutral to Buy and lowers the price target from $25 to $15.
seekingalpha.com Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside Alumis Inc. remains a late-stage biotech with no commercial product and significant risk. ALMS's value is primarily tied to envudeucitinib, a selective TYK2 inhibitor for psoriasis and lupus. The…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers bioAffinity Technologies (NASDAQ:BIAF) shares rose 43.1% to $6.53 during Tuesday's regular session. The company's market cap stands at $2.7 million. USBC (AMEX:USBC) stock moved upwards by…
seekingalpha.com Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript
benzinga.com Crude Oil Surges 3%; ISM Manufacturing PMI Falls In August U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Tuesday.The Dow traded down 0.40% to 52,971.81 while the NASDAQ dipped 0.52% to 26,232.46.…
marketbeat.com Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise Alumis NASDAQ: ALMS said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population.…
benzinga.com Why Is Alumis Stock Falling Tuesday? Alumis (ALMS) stock drops over 50% after Phase 2b lupus trial misses overall endpoints, but sub-group data shows promise.
benzinga.com Dow Dips Over 300 Points; Medtronic Shares Gain After Upbeat Q1 Earnings U.S. stocks traded lower this morning, with the Dow Jones index falling more than 300 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.58% to 52,876.43 while the NASDAQ…
reuters.com Alumis eyes late-stage lupus study despite trial miss Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related condition in a smaller subset of patients, even after the treatment failed to meet the main goal of a…
benzinga.com Alumis Announces Its Phase 2b LUMUS Study Of Envudeucitinib To Treat Lupus Erythematosus Failed To Meet Primary, Secondary Endpoints Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that its Phase 2b LUMUS…
globenewswire.com Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) – LUMUS trial did not meet its primary and secondary endpoints in the overall trial population – – Robust responses in the prespecified subgroup of patients with high interferon gene signature…- benzinga.com HC Wainwright & Co. Reiterates Neutral on Alumis, Maintains $25 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Neutral and maintains $25 price target.
- benzinga.com Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate Alumis (NASDAQ:ALMS) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.71) by 56.34 percent. This is a 12.6 percent increase over losses of $(1.27) per…
globenewswire.com Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements – ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO –
defenseworld.net California State Teachers Retirement System Raises Stock Position in Alumis Inc. $ALMS California State Teachers Retirement System boosted its holdings in shares of Alumis Inc. (NASDAQ: ALMS) by 2,222.5% in the first quarter, according to its most recent disclosure with the Securities…
zacks.com 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026 PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
benzinga.com Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates Alumis Inc. (NASDAQ:ALMS) on Monday shared topline data from its ongoing ONWARD3 long-term extension study, demonstrating that its investigational oral therapy, envudeucitinib, achieved leading skin…
benzinga.com Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates Alumis releases long-term data for psoriasis drug envudeucitinib, boasting top skin clearance rates ahead of a Q4 FDA filing with FDA.
benzinga.com Alumis Reports Topline Results From Ongoing ONWARD3 Long-Term Extension Study Showing 54% Of Patients Reached Complete Skin Clearance After 48 Weeks Of Continuous Envudeucitinib Treatment – Favorable long-term safety and tolerability profile remained consistent with previously reported data –– On track to submit a New Drug Application to FDA in 4Q 2026 –SOUTH SAN FRANCISCO, Calif.,…- benzinga.com HC Wainwright & Co. Reiterates Neutral on Alumis, Maintains $25 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Neutral and maintains $25 price target.
defenseworld.net Alumis (NASDAQ:ALMS) Shares Up 5.7% – What’s Next? Alumis Inc. (NASDAQ: ALMS - Get Free Report)'s share price was up 5.7% on Friday. The company traded as high as $28.64 and last traded at $28.78. 295,097 shares traded hands during trading, a decline…
seekingalpha.com Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon Alumis receives a renewed Buy rating, driven by upcoming data catalysts for lead candidate envudeucitinib in psoriasis and SLE. Phase 3 data for envudeucitinib showed strong efficacy and safety,…
benzinga.com This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday Top Wall Street analysts changed outlook on top names. DA Davidson initiated coverage on EBC & UNTY with Buy ratings. See other analyst views.
benzinga.com This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Top analysts changed outlook on top names. See all rating changes on analyst ratings page. Check out analysts' views on ALMS stock.
benzinga.com Expedia To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Monday Top analysts changed ratings for OVV, ALMS, CLMT, LGN, RCKT, UTHR, VNT, HOOD. See full changes at benzinga.com/analyst-stock-ratings
benzinga.com This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst ratings page. Analysts' thoughts on LGND stock.
benzinga.com This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday 
benzinga.com This Oracle Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday 
benzinga.com This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday 
benzinga.com Peakstone Realty Trust, Aquestive Therapeutics, Opera And Other Big Stocks Moving Higher On Monday 
benzinga.com This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday 
benzinga.com David Vs. Goliath: Why Small Cap Stocks Are Crushing The Magnificent 7 The Russell 2000 is beating the S&P 500 for 10 straight sessions as growth accelerates and small-cap earnings expectations rise.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com What's Going On With Alumis Stock Thursday? Alumis Inc. is drawing attention with a major share sale and bullish analyst forecasts. The firm aims to fund its immune disease pipeline.
benzinga.com Dow Jumps Over 400 Points; US Services Activity Falls In December